Shoring Up Osteoporosis Management: A Fresh Start?

IF 2.4 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of the American Board of Family Medicine Pub Date : 2024-05-01 DOI:10.3122/jabfm.2024.240060R0

Noah Furr, Ansley Ulmer, Brock Cardon

引用次数: 0

Abstract

Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.

查看原文本刊更多论文

加强骨质疏松症管理：重新开始？

与双磷酸盐相比，同化骨制剂，如甲状旁腺激素受体激动剂（特立帕肽和阿巴帕肽）和硬骨素抑制单克隆抗体（romosozumab），在预防患有或未患有严重骨质疏松症的女性发生临床意义上的骨折和/或脊椎骨折方面更具优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American Board of Family Medicine 医学-医学：内科

CiteScore

4.90

自引率

6.90%

发文量

168

审稿时长

4-8 weeks

期刊介绍： Published since 1988, the Journal of the American Board of Family Medicine ( JABFM ) is the official peer-reviewed journal of the American Board of Family Medicine (ABFM). Believing that the public and scientific communities are best served by open access to information, JABFM makes its articles available free of charge and without registration at www.jabfm.org. JABFM is indexed by Medline, Index Medicus, and other services.